Adaptive Phase III clinical trial
An adaptive Phase III clinical trial is a confirmatory randomized controlled trial that incorporates pre-specified rules allowing modifications to the trial design — such as sample size re-estimation, dose selection, or population enrichment — based on accumulating interim data, while preserving the Type I error rate. It sits at the top of the evidence hierarchy and is used to obtain regulatory approval of new interventions.
Kilderegistrering
Citater kopieret ordret fra metodens kilderegistrering. Ingen påstandsniveauverifikation er udledt heraf.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2019). ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials. ICH Harmonised Guideline. · URL
- U.S. Food and Drug Administration. (2019). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. FDA. · URL
Kuraterede påstande
Påstande gemt i bevis-loggen, hver med sin egen vurdering.
Denne visning opfinder ikke en påstandsvurdering, når loggen ingen har.
Relaterede metoder
Genereret fra metodegrafen og vist som maskinelt foreslåede relationer — ingen bevispåstand er udledt.